Report shows growth of the U.S. market for vascular access devices and accessories

Antimicrobial, Safety Devices and PICCs to Drive Market Growth

According to a new global report series by iData Research (www.idataresearch.net), the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for vascular access devices and accessories was valued at just over $3 billion in 2009 and is estimated to reach over $4.6 billion by 2016. The peripherally-inserted-central-catheters (PICCs) and midlines market is expected to see double-digit growth while the dialysis catheter market is expected to grow steadily due to the introduction of antimicrobial technology. The report also states that the antimicrobial central venous catheter (CVC) market was more than double the value of the conventional CVC market in 2009. In addition, growth of the antimicrobial CVC market is exceeding that of the conventional market.

Vascular access devices are used to gain access to a patient's bloodstream through the veins. The devices deliver a range of treatments including fluid infusion, parenteral nutrition, antibiotics, chemotherapy and dialysis. iData's new global series on the Markets for Vascular Access Devices and Accessories 2010 covers implantable-ports, Huber needles, CVCs, dialysis catheters, PICCs, midlines, PIVCs, ultrasound systems, catheter-securement-devices, syringes, needles and needleless connectors.

The report shows that the Needlestick Safety and Prevention Act has promoted sales of higher-priced safety devices, particularly with the advent of needleless connectors. In addition, the recent push to reduce catheter-related bloodstream infections through changes in Medicare and Medicaid reimbursement has been a major driver of growth in the overall vascular access market.

"The drive to reduce infection has been a major source of technological innovation in the vascular access market," says Dr. Kamran Zamanian, CEO of iData. "In an established market such as vascular access, market growth is driven by novel, higher-priced products."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The long-term cardiac impact of COVID-19